

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ATTORNEY DOCKET NO.:

SERIAL NO.:

INFORMATION DISCLOSURE STATEMENT

9619-1250

09/916,937

UNDER 37 CFR §1.56, §1.97, and §1.98

PTO-1449 FORM

APPLICANTS:

Lubock et al.

FILING DATE:


July 27, 2001

GROUP ART UNIT:

3736

U.S. PATENT DOCUMENTS

† EX'R INITIAL	*REF. #	PATENT NUMBER	DATE (MO/YR)	NAME	U.S. CLASS/ SUBCLASS	FILING DATE (If appropriate)
Can	*A1	Re. 0,033,925	5/1992	Bales et al.	600/48	12/1988
	*A2	Re. 0,034,056	9/1992	Lindgren et al.	428/754	
	*A3	2,032,860	3/1936	Wappler et al.		
	*A4	2,192,270	3/1940	McGowan		
	*A5	3,805,791	4/1974	Seuberth et al.		
	*A6	3,955,578	5/1976	Chamness et al.		
	*A7	4,007,732	2/1977	Kvavie et al.	428/2	9/1975
	*A8	4,202,338	5/1980	Bitroff		
	*A9	4,243,048	1/1981	Griffin	600/567	
	*A10	4,294,254	10/1981	Chamness		
	*A11	4,311,143	1/1982	Komiya		
	*A12	4,362,160	12/1982	Hiltebrandt	428/303-15	
	*A13	4,425,908	1/1984	Simon	428/4	10/1981
	*A14	4,503,855	3/1985	Maslanka		
	*A15	4,565,200	1/1986	Cosman	428/642	
	*A16	4,576,162	3/1986	McCorkle		
	*A17	4,592,356	6/1986	Gutierrez		
	*A18	4,616,656	10/1986	Nicholson et al.		
	*A19	4,638,802	1/1987	Okada		
	*A20	4,682,606	7/1987	DeCaprio	600/567	
	*A21	4,718,419	1/1988	Okada		
	*A22	4,724,836	2/1988	Okada		
	*A23	4,774,948	10/1988	Markham		
	*A24	4,909,250	3/1990	Smith		
	*A25	4,966,583	10/1990	Debbas	604/98	2/1989
	*A26	5,007,908	4/1991	Rydell		
	*A27	5,024,617	6/1991	Karpiel		
	*A28	5,035,696	7/1991	Rydell		
	*A29	5,037,379	8/1991	Clayman et al.		
	*A30	5,047,027	9/1991	Rydell	600/48	
	*A31	5,059,197	10/1991	Urie et al.		
	*A32	5,064,424	11/1991	Bitrolf	600/46	
	*A33	5,066,295	11/1991	Kozak et al.		
	*A34	5,078,716	1/1992	Doll		
	*A35	5,080,660	1/1992	Buelna		
	*A36	5,100,423	3/1992	Fearnot		
↓	*A37	5,111,828	5/1992	Kornberg et al.	428/754	9/1990
Can	*A38	5,133,359	7/1992	Kedem	428/754	



RECEIVED
APR - 1 2002
C 3700 MAIL ROOM

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ATTORNEY DOCKET NO.:

SERIAL NO.:

INFORMATION DISCLOSURE STATEMENT

9619-1250

09/916,937

UNDER 37 CFR §1.56, §1.97, and §1.98

PTO-1449 FORM

APPLICANTS:

Lubock et al.

FILING DATE:

July 27, 2001


GROUP ART UNIT:

3736

SHEET 2 OF 7

U.S. PATENT DOCUMENTS CONT'D

† EX'R INITIAL	*REF. #	PATENT NUMBER	DATE (MO/YR)	NAME	U.S. CLASS/ SUBCLASS	FILING DATE (If appropriate)
Can	*A39	5,147,307	9/1992	Gluck		
	*A40	5,158,084	10/1992	Ghiatas	128/657	11/1989
	*A41	5,158,561	10/1992	Rydell et al.		
	*A42	5,163,938	11/1992	Kambara et al.		
	*A43	5,192,270	3/1993	Carswell, Jr.	604/116	
	*A44	5,196,007	3/1993	Ellman et al.		
	*A45	5,201,732	4/1993	Parins et al.		
	*A46	5,201,741	4/1993	Dulebohn		
	*A47	5,207,686	5/1993	Dolgin		
	*A48	5,215,521	6/1993	Cochran et al.		
	*A49	5,217,458	6/1993	Parins	600/564	
	*A50	5,221,269	6/1993	Miller et al.		
	*A51	5,224,488	7/1993	Neuffer		
	*A52	5,234,426	8/1993	Rank et al.		
	*A53	5,281,218	1/1994	Imran	606/24	
	*A54	5,295,990	3/1994	Levin	606/49	9/1992
	*A55	5,304,176	4/1994	Phillips		
	*A56	5,312,400	5/1994	Bales et al.		
	*A57	5,318,564	6/1994	Eggers		
	*A58	5,323,768	6/1994	Saito et al.		
	*A59	5,324,288	6/1994	Billings et al.	606/45	
	*A60	5,335,671	8/1994	Clement		
	*A61	5,337,754	8/1994	Heaven et al.		
	*A62	5,344,420	9/1994	Hilal et al.		
	*A63	5,353,804	10/1994	Kornberg et al.		
	*A64	5,374,188	12/1994	Frank et al.		
	*A65	5,376,094	12/1994	Kline		
	*A66	5,380,321	1/1995	Yoon		
	*A67	5,395,312	3/1995	Desai		
	*A68	5,395,319	3/1995	Hirsh et al.		
	*A69	5,397,320	3/1995	Essig et al.	606/37	
	*A70	5,403,310	4/1995	Fisher		
	*A71	5,409,004	4/1995	Sloan		
	*A72	5,415,656	5/1995	Tihon et al.	606/46	
	*A73	5,417,687	5/1995	Nardella et al.	606/32	
	*A74	5,417,697	5/1995	Wilk et al.		
	*A75	5,423,814	6/1995	Zhu et al.		
↓	*A76	5,431,649	7/1995	Mulier et al.	606/41	
Can	*A77	5,437,665	8/1995	Munro	606/47	



RECEIVED
APR -1 2012
TC 8500 MAIL ROOM

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ATTORNEY DOCKET NO.:

SERIAL NO.:

INFORMATION DISCLOSURE STATEMENT

UNDER 37 CFR §1.56, §1.97, and §1.98

PTO-1449 FORM

9619-1250

09/916,937

APPLICANTS:

Lubock et al.

FILING DATE:

July 27, 2001

GROUP ART UNIT:

3736

SHEET 3 OF 7

U.S. PATENT DOCUMENTS CONT'D

† EXR INITIAL	*REF. #	PATENT NUMBER	DATE (MO/YR)	NAME	U.S. CLASS/ SUBCLASS	FILING DATE (If appropriate)
<i>Con</i>	*A78	5,441,503	8/1995	Considine et al.		
	*A79	5,449,382	9/1995	Dayton		
	*A80	5,462,553	10/1995	Dolgin		
	*A81	5,470,308	11/1995	Edwards et al.	604/22	
	*A82	5,484,436	1/1996	Eggers et al.		
	*A83	5,487,385	1/1996	Avitall	600/374	
	*A84	5,488,958	2/1996	Topel et al.	600/567	
	*A85	5,501,654	3/1996	Failla et al.		
	*A86	5,507,743	4/1996	Edwards et al.	606/41	8/1994
	*A87	5,509,916	4/1996	Taylor	606/43	8/1994
	*A88	5,526,822	6/1996	Burbank et al.	128/754	3/1994
	*A89	5,527,331	6/1996	Kresch et al.	606/170	9/1995
	*A90	5,542,948	8/1996	Weaver et al.		
	*A91	5,554,159	9/1996	Fischer		
	*A92	5,565,200	1/1986	Cosman		
	*A93	5,578,030	11/1996	Levin	606/49	
	*A94	5,578,031	11/1996	Wilk et al.	606/49	
	*A95	5,607,389	3/1997	Edwards et al.	604/22	11/1995
	*A96	5,611,803	3/1997	Heaven et al.		
	*A97	5,643,282	7/1997	Kieturakis		
	*A98	5,649,547	7/1997	Ritchart et al.	128/754	
	*A99	5,653,718	8/1997	Yoon		
	*A100	5,665,085	9/1997	Nardella		
	*A101	5,674,184	10/1997	Hassler, Jr.		
	*A102	5,683,384	11/1997	Gough et al.		
	*A103	5,687,739	11/1997	McPherson et al.	606/507	
	*A104	5,700,273	12/1997	Buelna et al.		
	*A105	5,715,825	2/1998	Crowley	128/602.06	
	*A106	5,720,763	2/1998	Tovey	606/198	
	*A107	5,730,726	3/1998	Klingenstein et al.	604/105	
	*A108	5,735,847	4/1998	Gough et al.	606/41	12/1995
	*A109	5,741,225	4/1998	Lax et al.	604/22	
	*A110	5,743,906	4/1998	Parins et al.	606/51	9/1996
	*A111	5,749,626	8/1998	Kieturakis		
	*A112	5,749,887	5/1998	Heske et al.	606/185	6/1995
	*A113	5,752,972	5/1998	Hoogeboom	606/205	11/1996
	*A114	5,755,697	5/1998	Jones et al.	604/174	11/1995
<i>Con</i>	*A115	5,766,163	6/1998	Mueller et al.		
<i>Con</i>	*A116	5,769,086	6/1998	Richart et al.		

RECEIVED
APR - 1 2002
3700 MAIL ROOM

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ATTORNEY DOCKET NO.:

SERIAL NO.:

INFORMATION DISCLOSURE STATEMENT

UNDER 37 CFR §1.56, §1.97, and §1.98

PTO-1449 FORM

9619-1250

09/916,937

APPLICANTS:

Lubock et al.

FILING DATE:

July 27, 2001

GROUP ART UNIT:

3736

SHEET 4 OF 7

U.S. PATENT DOCUMENTS CONT'D

† EX'R INITIAL	*REF. #	PATENT NUMBER	DATE (MO/YR)	NAME	U.S. CLASS/ SUBCLASS	FILING DATE (If appropriate)
Can	*A117	5,769,794	6/1998	Conlan et al.		
	*A118	5,772,660	6/1998	Young et al.	606/42	4/1997
	*A119	5,775,333	7/1998	Burbank et al.	128/754	5/1996
	*A120	5,782,764	7/1998	Werne	600/411	
	*A121	5,782,775	7/1998	Milliman et al.	600/567	
	*A122	5,788,709	8/1998	Riek et al.		
	*A123	5,794,626	8/1998	Kieturakis	600/567	
	*A124	5,795,308	8/1998	Russin		
	*A125	5,797,907	8/1998	Clement	606/49	
	*A126	5,800,378	9/1996	Edwards et al.	602/22	
	*A127	5,800,445	9/1998	Ratcliff et al.	606/416	10/1995
	*A128	5,810,806	9/1998	Ritchart et al.		
	*A129	5,814,044	9/1998	Hoooven	606/48	
	*A130	5,827,268	10/1998	Laufer	606/28	10/1998
	*A131	5,848,978	12/1998	Cecchi		
	*A132	5,853,366	12/1998	Dowlatsahi		
	*A133	5,857,981	1/1999	Bucalo et al.		
	*A134	5,857,982	1/1999	Milliman et al.		
	*A135	5,868,740	2/1999	LeVeen et al.		
	*A136	5,876,340	3/1999	Tu et al.	600/439	
	*A137	5,902,272	5/1999	Eggers et al.	604/114	
	*A138	5,913,857	6/1999	Ritchart et al.	606/45	
	*A139	5,925,044	7/1999	Hofmann et al.	606/45	6/1997
	*A140	5,928,164	7/1999	Burbank et al.	600/567	1/1998
	*A141	5,947,964	9/1999	Eggers et al.	606/41	
	*A142	5,954,670	9/1999	Baker	600/567	
	*A143	5,964,716	10/1999	Gregoire et al.	600/564	
	*A144	5,972,002	10/1999	Bark et al.	606/440	
	*A145	5,984,919	11/1999	Hilal et al.	606/45	11/1993
	*A146	6,004,269	12/1999	Crowley et al.	600/439	6/1995
	*A147	6,032,673	3/2000	Savage et al.	128/898	
	*A148	6,056,700	5/2000	Burney et al.		
✓	*A149	6,063,082	5/2000	DeVore et al.	606/45	3/1998
Can	*A150	6,161,034	12/2000	Burbank et al.		

FOREIGN PATENT DOCUMENTS

† EX'R INITIAL	*REF. #	PATENT NUMBER	DATE (MO/YR)	COUNTRY	TRANSLATION (YES/NO)
Can	*B1	9307811	4/1983	WO	No

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ATTORNEY DOCKET NO.:

SERIAL NO.:

INFORMATION DISCLOSURE STATEMENT

UNDER 37 CFR §1.56, §1.97, and §1.98

PTO-1449 FORM

9619-1250

09/916,937

APPLICANTS:

Lubock et al.

FILING DATE:

July 27, 2001

GROUP ART UNIT:

3736

SHEET 5 OF 7

FOREIGN PATENT DOCUMENTS CONT'D

† EX'R INITIAL	*REF. #	PATENT NUMBER	DATE (MO/YR)	COUNTRY	TRANSLATION (YES/NO)
Com	*B2	9313718	7/1993	WO	No
	*B3	9401536	7/1994	WO	No
	*B4	9401537	7/1994	WO	No
	*B5	9427670	12/1994	WO	No
	*B6	9502370	1/1995	WO	No
	*B7	9502371	1/1995	WO	No
	*B8	9503843	2/1995	WO	No
	*B9	9510317	4/1995	WO	No
	*B10	9713460	4/1997	WO	No
	*B11	97/29702 A1	8/1997	WO	No
	*B12	9735522	10/1992	WO	No
	*B13	9806346	2/1998	WO	No
	*B14	9808441	3/1998	WO	No
	*B15	98/084441	3/1990	WO	No
	*B16	9824372	6/1998	WO	No
	*B17	9904704	2/1999	WO	No
	*B18	9944506	9/1999	WO	No
	*B19	0016697	3/2000	WO	No
	*B20	19528440	8/1995	DE	No
	*B21	0472368	8/1991	EP	No
	*B22	0601709	6/1994	EP	No
	*B23	0667126	8/1995	EP	No
	*B24	0769 281	4/1997	EP	No
	*B25	0797957	1/1997	EP	No
↓	*B26	0858774 A2	8/1998	EP	No
Com	*B27	2311468	2/1997	GB	No

OTHER DOCUMENTS

† EX'R INITIAL	*REF. #	DOCUMENT DESCRIPTION (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES)
Com	*C1	Brachytherapy as Sole Method for Early Breast Cancer; R.R. Kuske MD, et al.; Chapter 80; Os/chsner Medical Institutions, New Orleans, LA.
	*C2	Clinical Thermochemotherapy, a Contolled Trial in Advanced Cancer Patients; F. Kristian Storm, MD, et al.; pp. 863-868
↓	*C4	Coaxial Core Needle Biopsy Under Mammographic Guidance: Indications and Applications, Whitman et al., AJR:171, Jul. 1998, pp. 67-70.
Com	*C5	The Dangers of Monopolar Electrosurgery and The Advantages of Bipolar Electrosurgery; Everest Medical; Technical Reviews; www.pycco.com/emc/techvws.htm; May 26, 1998.

TC 3700 MAIL ROOM

APR - 1 2002

11-11-02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ATTORNEY DOCKET NO.:

SERIAL NO.:

INFORMATION DISCLOSURE STATEMENT

UNDER 37 CFR §1.56, §1.97, and §1.98

PTO-1449 FORM

9619-1250

09/916,937

APPLICANTS:

Lubock et al.

FILING DATE:

July 27, 2001

GROUP ART UNIT:


3736

SHEET 6 OF 7

OTHER DOCUMENTS CONT'D

† EX'R INITIAL	*REF. #	DOCUMENT DESCRIPTION (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES)
Can	*C6	Database WPI, Derwent Publications #199711, citing German Patent No. DE 19528440 published Feb. 6, 1997.
	*C7	Endovascular Irradiation-A New Method to Avoid Recurrent Stenosis After Stent Implantation in Peripheral Arteries: Technique and Preliminary Results; H.D. Bottcher, MD et al.; 34 th Annual ASTRO Meeting, San Diego, CA, 11/92; Int. J. Radiation Oncology Biol. Phys., Vol. 29, No. 1, pp. 183-186, 1994.
	*C8	HDR Brachytherapy for Osteolytic Metastases in Previously Irradiated Sites; L.L. Doss FACP, et al., Chapter 101; Memorial Regional Cancer Center, Modesto, CA.
	*C9	Hepatic Metastases: Interstitial Laser Photocoagulation with Real-Time US Monitoring and Dynamic CT Evaluation of Treatment; Zahir Amin, MRCP et al.
	*C10	High Dose Rate Endovascular Irradiation: Tolerance of Normal Tissues; Kenneth E. Gehman, MD et al., ISSN 8756-1687; July 1994.
	*C11	Interstitial Bipolar RF-thermotherapy (RFITT) Therapy planning by computer simulation and MRI-monitoring - A new concept for minimally invasive procedures; K. Designer et al.; Laser - und Medizin Technologie gGmbH, Berlin, Krahmerstr. 6-10, D-12207 Berlin.
	*C12	Interstitial Hyperthermia of Colorectal Liver Metastases with a US-guided ND-YAG Laser with a Diffuser Tip: A Pilot Clinical Study; Christian P. Noise, MD et al.; Radiology
	*C13	Interstitial Laser Hyperthermia in Tumor Therapy; A. Masters and S.G. Brown; Annales Chirurgiae et Gynaecologica 79:244-251, 1990
	*C14	Interstitial Laser photocoagulation as a treatment for breast cancer; S.A. Harries et al., British Journal of Surgery 1994, 81, 1617-1619.
	*C15	Laser VS Electrosurgery; www.netvs.com/elmed/lasvselec.com; May 19, 1998
	*C16	Liver Photocoagulation with diode laser (805 nm) vs Nd:YAG laser (1064 nm).; SPIE Vol. 1646 Laser-Tissue Interaction III (1992) pp. 107-125.
	*C17	The Loop Electrode: a New Device for US-guided Interstitial Tissue Ablation Using Radio frequency Electrosurgery - An Animal Study, 1996 Blackwell Science Ltd. <i>Min Invas Ther & Allied Technol</i> , pp. 5 511-516.
	*C18	Moss' Radiation Oncology, Rationale, Technique, Results: Edited by James D. Cos, MD, FACR; Seventh Edition; Mosby, 1994.
	*C19	MR Imaging of Laser-Tissue Interactions; Ferenc A. Jolesz, MD et al.; Magnetic Resonance Imaging: 11/29/94; pp. 249-253.
	*C20	A New Application System for Simultaneous Laser and Ultrasonic Transmission in Endoscopic Surgery (LUST); K. Desinger et al., Laser- und Medizin Technologie gGmbH, Krahmerstr. 6-10, D-12207 Berlin, Germany.
✓	*C21	Nd:YAG Interstitial Laser Phototherapy Guided by Magnetic Resonance Imaging in an Ex Vivo Model: Dosimetry of Laser-MR-Tissue Interaction; Yoshimi Anzai, MD et al.; Laryngoscope 101: July 1991; pp. 755-760.
Can	*C22	Percutaneous Biopsy Techniques, Timothy J. Micklos, <i>Manual of Oncologic Therapeutics</i> (1989/1990), pp. 39-42.

RECEIVED
APR - 1 1992
FC 3700/11/1992

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56, §1.97, and §1.98 PTO-1449 FORM SHEET 7 OF 7		ATTORNEY DOCKET NO.: 9619-1250	SERIAL NO.: 09/916,937
		APPLICANTS: Lubock et al.	
		FILING DATE: July 27, 2001	GROUP ART UNIT: 3736
OTHER DOCUMENTS CONT'D			
† EX'R INITIAL	*REF. #	DOCUMENT DESCRIPTION (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES)	
Cm	*C23	Phototherapy of Tumors; by S.G. Grown, M.D.; University College Hospital, London, U.K.; World Journal of Surgery 7, 700-709, 1983	
	*C24	Stereotactic Breast Biopsy: Its History, Its Present, and Its Future, F. Burbank, M.D., <i>The American Surgeon</i> , Feb. 1996, vol. 62, pp. 128-150.	
	*C25	Temperature Mapping with MR Imaging of Molecular Diffusion: Application to Hyperthermia; Denis Le Bihan, MD, PhD, et al.; <i>Therapeutic Radiology</i> , June 1989; pp. 853-857.	
	*C26	Textbook of Radiotherapy, Third Edition; Lea & Febiger, 1980, Philadelphia; by Gilbert H. Fletcher, MD.	
	*C27	Ultrasound-Guided Cryosurgery for Tumor Ablation; March 22, 1995; Sheraton Bostox Hotel & Towers, Boston, MA; Sponsored by: Deconess Hospital.	
↓	*C28	International Search report for PCT, US 99/21416 mailed May 19, 2000.	
Cm	*C29	Written Opinion, mailed Jul. 18, 2000, PCT Rule 66, for International Application PCT/US/9921416.	
EXAMINER'S SIGNATURE <i>Charles Marmor, II</i>		DATE CONSIDERED <i>5/30/03</i>	
† EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609. Line through citation if not in conformance and not considered. Include copy of this form in next communication to applicant. * If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. 1.98(d).			

 RECEIVED
 APR - 1 2002
 TC 3700 MAIL ROOM


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT

UNDER 37 CFR §1.56, §1.97, and §1.98

PTO-1449 FORM

SHEET 1 OF 1



ATTORNEY DOCKET NO.:

09619.1250

SERIAL NO.:

09/916,937

APPLICANTS:

Lubock et al.

EXAMINER:

Not yet assigned

FILING DATE:

July 27, 2001

GROUP ART UNIT:

3736

U.S. PATENT DOCUMENTS

† EX'R INITIAL	*REF. #	PATENT NUMBER	DATE (MO/YR)	NAME	U.S. CLASS/ SUBCLASS	FILING DATE (If appropriate)
Can	A151	4,611,594	3/00	Grayhack et al.	—	

FOREIGN DOCUMENTS

† EX'R INITIAL	*REF. #	PATENT NUMBER	DATE (MO/YR)	COUNTRY	TRANSLATION (YES/NO)
Can	B28	WO 00/12009	3/00	WIPO	
Can	B29	WO 00/74561	12/00	WIPO	
Can	B30	WO 01/05320	1/01	WIPO	

OTHER DOCUMENTS

† EX'R INITIAL	*REF. #	Document Description (including author, Title, Date, Pertinent Pages, Etc.)
Can	C30	International Search Report for PCT/US02/20454 mailed November 29, 2002.

EXAMINER'S SIGNATURE

Charles Marmor, II

DATE CONSIDERED

5/30/03

† EXAMINER:

Initial if reference is considered, whether or not citation is in conformance with MPEP 609.

Line through citation if not in conformance and not considered.

Include copy of this form in next communication to applicant.

* If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. 1.98(d).